These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 33767387)

  • 1. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation.
    Ahn G; Banik SM; Miller CL; Riley NM; Cochran JR; Bertozzi CR
    Nat Chem Biol; 2021 Sep; 17(9):937-946. PubMed ID: 33767387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LYTACs: An Emerging Tool for the Degradation of Non-Cytosolic Proteins.
    Ramadas B; Kumar Pain P; Manna D
    ChemMedChem; 2021 Oct; 16(19):2951-2953. PubMed ID: 34296796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aptamer-LYTACs for Targeted Degradation of Extracellular and Membrane Proteins.
    Wu Y; Lin B; Lu Y; Li L; Deng K; Zhang S; Zhang H; Yang C; Zhu Z
    Angew Chem Int Ed Engl; 2023 Apr; 62(15):e202218106. PubMed ID: 36722696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conjugation with glucagon like peptide-1 enables targeted protein degradation.
    Zhu L; Zhou Y; Zhang B; Luo Y; Fang C; Yan X; Cai Y; Jiang L; Ge J
    Bioorg Chem; 2023 Dec; 141():106908. PubMed ID: 37827016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano-LYTACs for Degradation of Membrane Proteins and Inhibition of CD24/Siglec-10 Signaling Pathway.
    Wang K; Yu A; Liu K; Feng C; Hou Y; Chen J; Ma S; Huang L; Dai X
    Adv Sci (Weinh); 2023 May; 10(13):e2300288. PubMed ID: 36866919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic Site-Specific Antibody-Ligand Conjugates Promote Asialoglycoprotein Receptor-Mediated Degradation of Extracellular Human PCSK9.
    Donahue TC; Ou C; Yang Q; Flinko R; Zhang X; Zong G; Lewis GK; Wang LX
    ACS Chem Biol; 2023 Jul; 18(7):1611-1623. PubMed ID: 37368876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins.
    Zhou Y; Teng P; Montgomery NT; Li X; Tang W
    ACS Cent Sci; 2021 Mar; 7(3):499-506. PubMed ID: 33791431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras.
    Ahn G; Riley NM; Kamber RA; Wisnovsky S; Moncayo von Hase S; Bassik MC; Banik SM; Bertozzi CR
    Science; 2023 Oct; 382(6668):eadf6249. PubMed ID: 37856615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis.
    Zhou P; Zhang S; Li L; Zhang R; Guo G; Zhang Y; Wang R; Liu M; Wang Z; Zhao H; Yang G; Xie S; Ran J
    Theranostics; 2024; 14(13):4983-5000. PubMed ID: 39267779
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeted protein degradation combined with PET imaging reveals the role of host PD-L1 in determining anti-PD-1 therapy efficacy.
    Du J; Han S; Zhou H; Wang J; Wang F; Zhao M; Song R; Li K; Zhu H; Zhang W; Yang Z; Liu Z
    Eur J Nucl Med Mol Imaging; 2024 Oct; 51(12):3559-3571. PubMed ID: 38910165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysosome-targeting chimaeras for degradation of extracellular proteins.
    Banik SM; Pedram K; Wisnovsky S; Ahn G; Riley NM; Bertozzi CR
    Nature; 2020 Aug; 584(7820):291-297. PubMed ID: 32728216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IGF2 Peptide-Based LYTACs for Targeted Degradation of Extracellular and Transmembrane Proteins.
    Mikitiuk M; Barczyński J; Bielski P; Arciniega M; Tyrcha U; Hec A; Lipińska AD; Rychłowski M; Holak TA; Sitar T
    Molecules; 2023 Nov; 28(22):. PubMed ID: 38005242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs.
    Agarwal S; Allard R; Darcy J; Chigas S; Gu Y; Nguyen T; Bond S; Chong S; Wu JT; Janas MM
    Nucleic Acid Ther; 2021 Aug; 31(4):309-315. PubMed ID: 33861634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.
    Willoughby JLS; Chan A; Sehgal A; Butler JS; Nair JK; Racie T; Shulga-Morskaya S; Nguyen T; Qian K; Yucius K; Charisse K; van Berkel TJC; Manoharan M; Rajeev KG; Maier MA; Jadhav V; Zimmermann TS
    Mol Ther; 2018 Jan; 26(1):105-114. PubMed ID: 28988716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR).
    Zhang Y; Zhang X; Zeng C; Li B; Zhang C; Li W; Hou X; Dong Y
    Bioorg Med Chem; 2019 Jun; 27(11):2187-2191. PubMed ID: 31005367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivalent Aptamer-Based Lysosome-Targeting Chimeras (LYTACs) Platform for Mono- or Dual-Targeted Proteins Degradation on Cell Surface.
    Duan Q; Jia HR; Chen W; Qin C; Zhang K; Jia F; Fu T; Wei Y; Fan M; Wu Q; Tan W
    Adv Sci (Weinh); 2024 May; 11(17):e2308924. PubMed ID: 38425146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligands of the asialoglycoprotein receptor for targeted gene delivery, part 1: Synthesis of and binding studies with biotinylated cluster glycosides containing N-acetylgalactosamine.
    Westerlind U; Westman J; Törnquist E; Smith CI; Oscarson S; Lahmann M; Norberg T
    Glycoconj J; 2004; 21(5):227-41. PubMed ID: 15486455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted degradation of membrane and extracellular proteins with LYTACs.
    Li YY; Yang Y; Zhang RS; Ge RX; Xie SB
    Acta Pharmacol Sin; 2024 Aug; ():. PubMed ID: 39103530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Oligomeric Mannose-6-phosphonate Conjugates for Targeted Protein Degradation.
    Stevens CM; Zhou Y; Teng P; Rault LN; Liao Y; Tang W
    ACS Med Chem Lett; 2023 Jun; 14(6):719-726. PubMed ID: 37312839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Directed evolution of genetically encoded LYTACs for cell-mediated delivery.
    Yang JL; Yamada-Hunter SA; Labanieh L; Sotillo E; Cheah JS; Roberts DS; Mackall CL; Bertozzi CR; Ting AY
    Proc Natl Acad Sci U S A; 2024 Mar; 121(13):e2320053121. PubMed ID: 38513100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.